Neuropathic pain due to orthopedic diseases
Conditions
Interventions
Patients with neuropathic pain due to orthopedic diseases are treated with oral mirogabalin besilate tablets for 8 weeks. Patients with neuropathic pain due to orthopedic diseases are provided with pa
Sponsors
Nakashima Hiroaki
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed with neuropathic pain due to orthopedic disorders 2. First patient treated with a neuropathic pain medication 3. Patients who are scheduled to continue treatment for at least 8 weeks and are able to attend the relevant medical institution 4. Patients aged 18 years or older at the time of obtaining informed consent 5. Patients who can understand the procedure of this study, answer questions in Japanese appropriately in writing and by electromagnetic means (ePRO) without assistance, and give their own written consent on their own free will to participate in this study by writing or electromagnetic means (eConsent)
Exclusion criteria
Exclusion criteria: 1. Patients who are considered to require inpatient treatment at the time of study entry 2. Patients scheduled to undergo surgery during the study period 3. Patients with severe pain attributable to a disease other than the relevant disease and considered difficult to evaluate. 4. Patients with creatinine clearance (CLcr) <30 mL/min 5. Patients with complicated serious liver, kidney, and heart disease 6. Patients who are pregnant or possibly pregnant at the time of obtaining informed consent, patients who are breastfeeding at the time of obtaining informed consent, and patients who intend to become pregnant within 6 months after obtaining informed consent 7. Patients participating in or planned to participate in other intervention studies at enrollment 8. Other patients judged by the principal investigator or subinvestigator to be ineligible for participation in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patient treatment satisfaction | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Factors affecting patient treatment satisfaction. 2. Association Between Disease/Medication Understanding and Patient Treatment Satisfaction at Week 8. 3. Association between disease/drug comprehension and various items at Week 8 4. Change from baseline in disease/drug comprehension (Week 8) 5. Association between physician treatment satisfaction and various items. 6. Concordance between patients and physicians with various items. 8. Adverse events (TEAE) | — |
Contacts
Public ContactYosuke Sawa
EPS Corporation
Outcome results
None listed